Compare Hims and Hers Health Inc (HIMS) vs Lucid Group Inc (LCID) Price & Performance

Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.

The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.

Lucid Group (LCID) trades at $3.89, down 6.49% today, reflecting ongoing investor concerns about the company's financial health. The stock shows bearish technical signals with negative moving averages and faces significant fundamental challenges including massive losses, negative profit margins, and substantial cash burn. Recent developments include strategic partnerships for autonomous vehicles but also product delays and cost-cutting initiatives as the company navigates a critical turnaround phase.

LCID presents high-risk speculative potential with a consensus price target of $7.60 representing 95% upside, but faces existential challenges including potential bankruptcy risk, consistent earnings misses, and negative cash flow. The company's survival depends on successful execution of cost savings initiatives and new product launches, making this suitable only for risk-tolerant investors comfortable with substantial volatility and potential loss.